NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
| Website: | www.neogenomics.com |
| Email: | bill.bonello@neogenomics.com |
| Main Phone: | +1 239 768-0600 |
| Address: | 12701 Commonwealth Drive |
| Address 2: | Suite 9 |
| State: | FL |
| City / Town: | Fort Myers |
| Country: | USA |
| Postal Code: | 33913 |
| Exchange: | NSC |
| CEO: | Douglas M. VanOort |
| Employees: | 1700 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
Four companies that look strong via technical analysis.
Robotics and artificial intelligence are setting the stage for longer lifespans and new investment opportunities.
Comprehensive testing is invaluable when it comes to cancer research. About 595,690 Americans are expected to die of cancer in 2016, which translates to about 1,630 people per day. Cancer is the second most common cause of death in the US, exceeded only by
The Equities.com research team took a bold shot when it went against conventional wisdom (and Carl Icahn) by suggesting that Apple (AAPL) , the most valuable company in the world, was also
Investing in small-cap healthcare companies is frequently a frustratingly inconsistent proposition. As often as not, you’re dealing with companies that defy analysis through conventional
Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular
Shares for Sears Holdings Corp. (SHLD) plummeted some 13.4 percent on Friday, after dropping some 12.4 in early trading, a response to the dismal earnings report the company released late the
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
| Website: | www.neogenomics.com |
| Email: | bill.bonello@neogenomics.com |
| Main Phone: | +1 239 768-0600 |
| Address: | 12701 Commonwealth Drive |
| Address 2: | Suite 9 |
| State: | FL |
| City / Town: | Fort Myers |
| Country: | USA |
| Postal Code: | 33913 |
| Exchange: | NSC |
| CEO: | Douglas M. VanOort |
| Employees: | 1700 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
Four companies that look strong via technical analysis.
Robotics and artificial intelligence are setting the stage for longer lifespans and new investment opportunities.
Comprehensive testing is invaluable when it comes to cancer research. About 595,690 Americans are expected to die of cancer in 2016, which translates to about 1,630 people per day. Cancer is the second most common cause of death in the US, exceeded only by
The Equities.com research team took a bold shot when it went against conventional wisdom (and Carl Icahn) by suggesting that Apple (AAPL) , the most valuable company in the world, was also
Investing in small-cap healthcare companies is frequently a frustratingly inconsistent proposition. As often as not, you’re dealing with companies that defy analysis through conventional
Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular
Shares for Sears Holdings Corp. (SHLD) plummeted some 13.4 percent on Friday, after dropping some 12.4 in early trading, a response to the dismal earnings report the company released late the
| Last Price 28.18 | Change $ 0.36 | Change % 1.29 | Tick N/A |
| Bid 27.25 | Bid Size 200.00 | Ask 28.20 | Ask Size 100.00 |
| Open 27.86 | High 28.27 | Low 27.23 | Prev Close 27.82 |
| Last Trade | Volume 575,837 | 52 Wk Hi 34.97 | 52 Wk Low 18.53 |
| Market Cap 3.1 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 109,735,242.00 | EPS (TTM) 0.03 | PE Ratio 939.30 | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 32 | 42 |
| Number of Buys | 20 | 26 |
| Number of Sells | 12 | 16 |
| Net Activity | -231499 | -228889 |
| Last 10 Buys | Shares |
|---|---|
| Alison L. Hannah | 1,000 |
| Kevin Johnson | 1,000 |
| Alison L. Hannah | 1,000 |
| Kevin Johnson | 1,000 |
| Lynn A. Tetrault | 1,000 |
| Lynn A. Tetrault | 1,000 |
| Robert J. Shovlin | 1,000 |
| Bruce K. Crowther | 1,000 |
| Maher Albitar | 1,000 |
| Stephen J. Clearman | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Steven C. Jones | 1,000 |
| Steven C. Jones | 1,000 |
| Steven C. Jones | 1,000 |
| Steven C. Jones | 1,000 |
| Jennifer Balliet | 1,000 |
| Jennifer Balliet | 1,000 |
| Jennifer Balliet | 1,000 |
| Jennifer Balliet | 1,000 |
| Steven A. Ross | 1,000 |
| Jennifer Balliet | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 13 | 11 | 11 | 14 |
| Low Target Price Estimate | 10 | 10 | 10 | 10 |
| Mean Target Price Estimate | 11.2 | 10.8 | 10.8 | 11.8 |
| Standard Deviation | 1.1 | 0.45 | 0.45 | 1.64 |
| Date of Most Recent Estimate | 06/04/18 | 05/15/18 | 05/02/18 | 06/07/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 40 | 2018-06-12 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-06 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-06-01 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-31 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.33 | 1.33 | 1.29 | 1.38 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait